Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction

Journal of cardiology
Yoshinori NakamuraHisao Ogawa

Abstract

Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the pathogenesis of acute coronary syndrome. We have recently demonstrated that the administration of edaravone before reperfusion attenuated reperfusion injury in patients with acute myocardial infarction (AMI). Plasma MCP-1 levels were measured in 45 consecutive patients with AMI (edaravone group, n=25; control group, n=20). In the edaravone group, 30 mg edaravone was intravenously infused just before reperfusion. Plasma samples were obtained before and at 24h, 3, 5, 7, and 14 days after reperfusion. Cardiovascular events were defined as cardiac death, subacute thrombosis, or fatal arrhythmia. Heart failure requiring rehospitalization was evaluated at 12 months after reperfusion. Plasma MCP-1 levels were not different between the two groups before reperfusion. Compared with the placebo group, the edaravone group had statistically lower maximum creatine kinase-MB levels (218±31 IU/l versus 145±21 IU/l, p<0.05) and plasma MCP-1 levels on day 3 after reperfusion (873±118 pg/ml versus 516±66 pg/ml, p<0.05). Heart failure requiring rehospitalization occurred in four patients in the control group, but did not occur in the edaravone group (p<0.05). At 12 months af...Continue Reading

References

Jun 1, 1978·Chest·M C FishbeinP R Maroko
Sep 1, 1989·Stroke; a Journal of Cerebral Circulation·H NishiA Ishibashi
Apr 1, 1988·Stroke; a Journal of Cerebral Circulation·K AbeK Kogure
Jan 17, 1985·The New England Journal of Medicine·J M McCord
Sep 1, 1994·Cardiovascular Research·M L Entman, C W Smith
Jan 1, 1994·Immunology Today·T M Buttke, P A Sandstrom
Feb 18, 1997·Circulation·E T Yeh
Feb 14, 1998·The Journal of Clinical Investigation·M ArrasW Schaper
Feb 12, 1998·The New England Journal of Medicine·A D Luster
Nov 24, 1999·Atherosclerosis·T J Reape, P H Groot
Dec 18, 2003·Clinical Cardiology·Hirofumi SoejimaHisao Ogawa
Aug 25, 2004·The American Journal of Cardiology·Kenichi TsujitaHisao Ogawa
Nov 26, 2005·Circulation Journal : Official Journal of the Japanese Circulation Society·Ivo MartinovicStephan Lindemann
Feb 28, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Takanori HayasakiMotohiro Takeya
Jun 27, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Kenichi TsujitaHisao Ogawa
Nov 27, 2007·Journal of the American College of Cardiology·James A de LemosEugene Braunwald
Nov 26, 2008·Journal of cardiology·Masaharu IshiharaHiroki Ikenaga
Nov 26, 2008·Journal of cardiology·Jun MurakamiMasahiko Kurabayashi

❮ Previous
Next ❯

Citations

Jul 25, 2013·International Journal of Molecular Sciences·Kiyoshi KikuchiEiichiro Tanaka
Mar 1, 2012·Journal of cardiology·Takashi KohnoKeiichi Fukuda
Jun 25, 2017·American Journal of Physiology. Heart and Circulatory Physiology·Junco Shibayama WarrenJunichi Sadoshima
Dec 26, 2017·Hospital Pharmacy·Zaynah K Ali, Danial E Baker
Feb 19, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Yuji MiyazakiYuichi Oike
Oct 21, 2018·Journal of Cellular Physiology·Aynaz MihanfarMohammad Nouri
Jul 10, 2020·Antioxidants & Redox Signaling·Erica GianazzaCristina Banfi
Sep 13, 2012·Experimental and Therapeutic Medicine·Kiyoshi KikuchiKo-Ichi Kawahara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.